Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas

Oncogene volume 19, pages 5858–5862 (2000)Cite this article

Abstract

Overrepresentation of 12p-sequences, mostly due to isochromosome formation, is the only consistent chromosomal alteration found in invasive testicular germ cell tumors of adolescents and young adults (TGCTs), both seminomas and the various histological elements of nonseminomas. The biological role of extra 12p in the pathogenesis of this cancer is unclear, and it is also unknown so far, whether it is an early event, i.e., already present in carcinoma in situ, or related to invasive growth. Using comparative genomic hybridization (CGH) with DOP-PCR amplified DNA isolated from micro-dissected tumor cells, and double fluorescent in situ hybridization (FISH) on frozen tissue sections, we investigated the presence of overrepresentation of 12p sequences in different development stages of four seminomas and seven nonseminomas, in total 17 invasive components, in addition to the carcinoma in situ of each. CGH demonstrated relative gain of 12p-sequences in all invasive components except one, confirmed by FISH in most samples. In contrast, no gain was found in the carcinoma in situ samples by any of the methods. These findings show that overrepresentation of 12p is not an early event in the development of TGCTs, but relates to invasive growth.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Adami HO, Bergström R, Möhner M, Zatonski W, Storm H, Ekbom A, Tretli S, Teppo L, Ziegler H, Rahu M, Gurevicius R and Stengrevics A. . 1994 Int. J. Cancer 59: 33–38.

  • Atkin NB and Baker MC. . 1982 The Lancet. 11: 1349.

  • De Graaff WE, Oosterhuis JW, De Jong B, Dam A, Van Putten WLJ, Castedo SMMJ, Sleijfer DT and Schraffordt Koops H. . 1992 Lab. Invest. 66: 166–168.

  • Geurts van Kessel A, Van Drunen E, De Jong B, Oosterhuis JW, Langeveld A and Mulder MP. . 1989 Cancer Genet Cytogenet. 40: 129–134.

  • Gondos B. . 1993 Eur. Urol. 23: 68–75.

  • Jørgensen N, Rajpert-De Meyts E, Graem N, Müller J, Giwercman A and Skakkebæk NE. . 1995 Lab. Invest. 72: 223–231.

  • Korn MW, Olde Weghuis DEM, Suijkerbuijk RF, Schmidt U, Otto T, Du Manoir S, Geurts van Kessel A, Seeber S and Becher R. . 1996 Genes Chrom. Cancer 17: 8–87.

  • Looijenga LHJ and Oosterhuis JW. . 1999 Rev. Reprod. 4: 90–100.

  • Looijenga LHJ, Rosenberg C, Van Gurp RJHLM, Geelen E, Van Echten-Arends J, De Jong B, Mostert MC and Oosterhuis JW. . 2000 J. Pathol. 191: 187–192.

  • Looijenga LHJ, Smith VTHBM, Wessels JW, Mollevanger P, Oosterhuis JW, Cornelisse CJ and Devilee P. . 1990 Cytogenet Cell Genet. 53: 216–218.

  • Moller H. . 1989 J. Natl. Cancer Inst. 81: 1668–1669.

  • Mosselman S, Looijenga LHJ, Gillis AJM, Van Rooijen MA, Kraft HJ, Van Zoelen EJJ and Oosterhuis JW. . 1996 Proc. Natl. Acad. Sci. USA 93: 2884–2888.

  • Mostert MC, Van de Pol M, Van Echten J, Olde Weghuis D, Geurts van Kessel A, Oosterhuis JW and Looijenga LHJ. . 1996 Cancer Genet. Cytogenet. 87: 95–102.

  • Mostert MC, Verkerk AJMH, Van de Pol M, Heighway J, Marynen P, Rosenberg C, Geurts van Kessel A, van Echten J, Oosterhuis JW and Looijenga LHJ. . 1998 Oncogene 16: 2617–2627.

  • Mostofi FK and Sesterhenn IA. . 1998 Histological typing of testis tumors. pp.132. Berlin, Springer.

  • Oosterhuis JW, Castedo SM, De Jong B, Cornelisse CJ, Dam A, Sleijfer DT and Schraffordt Koops H. . 1989 Lab. Invest. 60: 14–21.

  • Ottesen AM, Kirchhoff M, Rajpert De-Meyts E, Maahr J, Gerdes T, Rose H, Lundsteen C, Meidahl Petersen P, Philip J and Skakkebæk NE. . 1997 Genes Chromo. Cancer. 20: 412–418.

  • Rodriguez E, Houldsworth J, Reuter VE, Meltzer P, Zhang J, Trent JM, Bosl GJ and Chaganti RSK. . 1993 Genes Chromo. Cancer 8: 230–236.

  • Roelofs H, Mostert MC, Pompe K, Zafarana G, Van Oorschot M, Van Gurp RHJLM, Gillis AJM, Stoop H, Beverloo B, Oosterhuis JW, Bokemeyer C and Looijenga LHJ. . 2000 Am. J. Pathol. 157: 1155–1166.

  • Rosenberg C, Bakker Schut T, Mostert MC, Tanke HJ, Raap AK, Oosterhuis JW and Looijenga LHJ. . 1999 Lab. Invest. 79: 1447–1451.

  • Rosenberg C, Van Gijlswijk RP, Vos CBJ, Wiegant J, Cornelisse CJ, Tanke HJ and Raap AK. . 1998 Cytometry 32: 337–341.

  • Sandberg AA, Meloni AM and Suijkerbuijk RF. . 1996 J. Urol. 155: 1531–1556.

  • Skakkebæk NE, Berthelsen JG, Giwercman A and Muller J. . 1987 Int. J. Androl. 10: 19–28.

  • Suijkerbuijk RF, Sinke RJ, Meloni AM, Parrington JM, van Echten J, De Jong B, Oosterhuis JW, Sandberg AA and Geurts van Kessel A. . 1993 Cancer Genet Cyto. 70: 85–93.

  • Suijkerbuijk RF, Sinke RJ, Olde Weghuis DEM, Roque L, Forus A, Stellink F, Siepman A, Van de Kaa C, Soares J and Geurts van Kessel A. . 1994 Cancer Genet Cyto. 78: 145–152.

  • Summersgill B, Goker H, Wber-Hall S, Huddart R, Horwich A and Shipley J. . 1998 Br. J. Cancer. 77: 305–313.

  • Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA and Tunnacliffe A. . 1992 Genomics. 13: 718–725.

  • van Echten J, Sleijfer DT, Wiersema J, Schraffordt Koops H, Oosterhuis JW and de Jong B. . 1997 Cancer Genet Cytogenet. 96: 1–6.

  • van Echten-Arends J, Stoepker M, Leegte B, Looijenga LHJ, De Jong B and Oosterhuis JW. . 1994 Cancer Genet Cytogenet. 77: 194.

  • Vorechovsky I and Mazanec K. . 1989 Neoplasma 36: 697–700.

  • Vos A, Oosterhuis JW, De Jong B, Buist J and Schraffordt Koops H. . 1990 Cancer Genet Cytogenet. 46: 75–81.

Download references

Acknowledgements

We thank the pathologists and urologists in the south-western part of The Netherlands for their help in collecting the tumor samples. This work has been supported by the Dutch Cancer Society (KWF, DDHK 94 836) and the Post Graduate School Molecular Medicine.

Author information

Author notes

  1. C Rosenberg and R J H L M Van Gurp: C Rosenberg and RJHLM Van Gurp contributed equally to the work.

Authors and Affiliations

  1. Department of Cytochemistry and Cytometry, Leiden University Medical Center, Leiden, The Netherlands

    C Rosenberg & E Geelen

  2. Pathology/Laboratory for Experimental Patho-Oncology, University Hospital Rotterdam/Daniel, Josephine Nefkens Institute, Rotterdam, The Netherlands

    R J H L M Van Gurp, E Geelen, J W Oosterhuis & L H J Looijenga

Authors
  1. C Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R J H L M Van Gurp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Geelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J W Oosterhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L H J Looijenga
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenberg, C., Van Gurp, R., Geelen, E. et al. Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. Oncogene 19, 5858–5862 (2000). https://doi.org/10.1038/sj.onc.1203950

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203950

Keywords

This article is cited by

Search

Advanced search

Quick links